{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:51:36Z","timestamp":1794430296526,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","award":["Postgraduate Scholarship (Merck PhD Scholarship in Medicine)"],"award-info":[{"award-number":["Postgraduate Scholarship (Merck PhD Scholarship in Medicine)"]}],"id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIAMS K01AR075879"],"award-info":[{"award-number":["NIAMS K01AR075879"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nordic Bioscience"},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["Investigator Fellowship"],"award-info":[{"award-number":["Investigator Fellowship"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To assess the prognostic value of short-term change in biochemical markers as it relates to bone marrow lesions (BMLs) on MRI in knee osteoarthritis (OA) over 24\u00a0months and, furthermore, to assess the relationship between biochemical markers involved with tissue turnover and inflammation and BMLs on MRI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from the Foundation for the National Institutes of Health OA Biomarkers Consortium within the Osteoarthritis Initiative (<jats:italic>n<\/jats:italic>\u2009=\u2009600) was analyzed. BMLs were measured according to the MRI Osteoarthritis Knee Score (MOAKS) system (0\u20133), in 15 knee subregions. Serum and urinary biochemical markers assessed were as follows: serum C-terminal crosslinked telopeptide of type I collagen (CTX-I), serum crosslinked N-telopeptide of type I collagen (NTX-I), urinary CTX-I\u03b1 and CTX-I\u03b2, urinary NTX-I, urinary C-terminal cross-linked telopeptide of type II collagen (CTX-II), serum matrix metalloproteinase (MMP)-degraded type I, II, and III collagen (C1M, C2M, C3M), serum high sensitivity propeptide of type IIb collagen (hsPRO-C2), and matrix metalloproteinase-generated neoepitope of C-reactive protein (CRPM). The association between change in biochemical markers over 12\u00a0months and BMLs over 24\u00a0months was examined using regression models adjusted for covariates. The relationship between C1M, C2M, C3M, hsPRO-C2, and CRPM and BMLs at baseline and over 24\u00a0months was examined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Increases in serum CTX-I and urinary CTX-I\u03b2 over 12\u00a0months were associated with increased odds of changes in the number of subregions affected by any BML at 24\u00a0months. Increase in hsPRO-C2 was associated with decreased odds of worsening in the number of subregions affected by any BML over 24\u00a0months. C1M and C3M were associated with BMLs affected at baseline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Short-term changes in serum CTX-I, hsPRO-C2, and urinary CTX-I\u03b2 hold the potential to be prognostic of BML progression on MRI. The association of C1M and C3M with baseline BMLs on MRI warrants further investigation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-023-03253-x","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T09:02:57Z","timestamp":1705568577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Association of biochemical markers with bone marrow lesion changes on imaging\u2014data from the Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2223-2182","authenticated-orcid":false,"given":"Shirley P.","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia A.","family":"Deveza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia B.","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Christine","family":"Bay-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie E.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Guermazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W.","family":"Roemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Ladel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesha","family":"Bhagavath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"issue":"4","key":"3253_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/bor.0000000000000181","volume":"27","author":"T Funck-Brentano","year":"2015","unstructured":"Funck-Brentano T, Cohen-Solal M. Subchondral bone and osteoarthritis. Curr Opin Rheumatol. 2015;27(4):420\u20136. https:\/\/doi.org\/10.1097\/bor.0000000000000181.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"3253_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.joca.2022.09.007","volume":"31","author":"DA Walsh","year":"2023","unstructured":"Walsh DA, Sofat N, Guermazi A, et al. Osteoarthritis bone marrow lesions. Osteoarthritis Cartilage. 2023;31(1):11\u20137. https:\/\/doi.org\/10.1016\/j.joca.2022.09.007.","journal-title":"Osteoarthritis Cartilage"},{"issue":"12","key":"3253_CR3","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/rheumatology\/keq286","volume":"49","author":"SK Tanamas","year":"2010","unstructured":"Tanamas SK, Wluka AE, Pelletier JP, et al. Bone marrow lesions in people with knee osteoarthritis predict progression of disease and joint replacement: a longitudinal study. Rheumatology (Oxford). 2010;49(12):2413\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keq286.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"3253_CR4","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1136\/ard.2008.096834","volume":"68","author":"FW Roemer","year":"2009","unstructured":"Roemer FW, Guermazi A, Javaid MK, et al. Change in MRI-detected subchondral bone marrow lesions is associated with cartilage loss: the MOST study. A longitudinal multicentre study of knee osteoarthritis. Ann Rheum Dis. 2009;68(9):1461\u20135. https:\/\/doi.org\/10.1136\/ard.2008.096834.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"3253_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.7326\/0003-4819-134-7-200104030-00007","volume":"134","author":"DT Felson","year":"2001","unstructured":"Felson DT, Chaisson CE, Hill CL, et al. The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med. 2001;134(7):541\u20139. https:\/\/doi.org\/10.7326\/0003-4819-134-7-200104030-00007.","journal-title":"Ann Intern Med"},{"issue":"8","key":"3253_CR6","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/annrheumdis-2011-200970","volume":"71","author":"LL Laslett","year":"2012","unstructured":"Laslett LL, Dore DA, Quinn SJ, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis. 2012;71(8):1322\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200970.","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"3253_CR7","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2020.2938","volume":"323","author":"G Cai","year":"2020","unstructured":"Cai G, Aitken D, Laslett LL, et al. Effect of intravenous zoledronic acid on tibiofemoral cartilage volume among patients with knee osteoarthritis with bone marrow lesions: a randomized clinical trial. JAMA. 2020;323(15):1456\u201366. https:\/\/doi.org\/10.1001\/jama.2020.2938.","journal-title":"JAMA"},{"issue":"2","key":"3253_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/annrheumdis-2013-203989","volume":"74","author":"JP Pelletier","year":"2015","unstructured":"Pelletier JP, Roubille C, Raynauld JP, et al. Disease-modifying effect of strontium ranelate in a subset of patients from the phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss. Ann Rheum Dis. 2015;74(2):422\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203989.","journal-title":"Ann Rheum Dis"},{"issue":"5\u20136","key":"3253_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.rehab.2016.07.004","volume":"59","author":"A Mobasheri","year":"2016","unstructured":"Mobasheri A, Batt M. An update on the pathophysiology of osteoarthritis. Ann Phys Rehabil Med. 2016;59(5\u20136):333\u20139. https:\/\/doi.org\/10.1016\/j.rehab.2016.07.004.","journal-title":"Ann Phys Rehabil Med"},{"issue":"1","key":"3253_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/BOR.0000000000000567","volume":"31","author":"A Mobasheri","year":"2019","unstructured":"Mobasheri A, van Spil WE, Budd E, et al. Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes. Curr Opin Rheumatol. 2019;31(1):80\u20139. https:\/\/doi.org\/10.1097\/BOR.0000000000000567.","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"3253_CR11","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.joca.2010.01.012","volume":"18","author":"WE van Spil","year":"2010","unstructured":"van Spil WE, Degroot J, Lems WF, et al. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthritis Cartilage. 2010;18(5):605\u201312. https:\/\/doi.org\/10.1016\/j.joca.2010.01.012. (S1063-4584(10)00042-7 [pii]).","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"3253_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1136\/annrheumdis-2016-209252","volume":"76","author":"VB Kraus","year":"2017","unstructured":"Kraus VB, Collins JE, Hargrove D, et al. Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers consortium. Ann Rheum Dis. 2017;76(1):186\u201395. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209252.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3253_CR13","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.joca.2021.04.019","volume":"30","author":"VB Kraus","year":"2022","unstructured":"Kraus VB, Karsdal MA. Clinical monitoring in osteoarthritis: biomarkers. Osteoarthritis Cartilage. 2022;30(9):1159\u201373. https:\/\/doi.org\/10.1016\/j.joca.2021.04.019.","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"3253_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.berh.2014.01.007","volume":"28","author":"DJ Hunter","year":"2014","unstructured":"Hunter DJ, Nevitt M, Losina E, et al. Biomarkers for osteoarthritis: current position and steps towards further validation. Best Pract Res Clin Rheumatol. 2014;28(1):61\u201371. https:\/\/doi.org\/10.1016\/j.berh.2014.01.007.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"3253_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/art.40348","volume":"70","author":"VB Kraus","year":"2018","unstructured":"Kraus VB, Collins JE, Charles HC, et al. Predictive validity of radiographic trabecular bone texture in knee osteoarthritis: the osteoarthritis research society international\/foundation for the national institutes of health osteoarthritis biomarkers consortium. Arthritis Rheumatol. 2018;70(1):80\u20137. https:\/\/doi.org\/10.1002\/art.40348.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"3253_CR16","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1002\/art.39731","volume":"68","author":"JE Collins","year":"2016","unstructured":"Collins JE, Losina E, Nevitt MC, et al. Semiquantitative imaging biomarkers of knee osteoarthritis progression: data from the foundation for the national institutes of health osteoarthritis biomarkers consortium. Arthritis Rheumatol. 2016;68(10):2422\u201331. https:\/\/doi.org\/10.1002\/art.39731.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"3253_CR17","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/acr.24557","volume":"74","author":"DJ Hunter","year":"2022","unstructured":"Hunter DJ, Deveza LA, Collins JE, et al. Multivariable modeling of biomarker data from the phase i foundation for the national institutes of health osteoarthritis biomarkers consortium. Arthritis Care Res (Hoboken). 2022;74(7):1142\u201353. https:\/\/doi.org\/10.1002\/acr.24557.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"3253_CR18","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1016\/j.ejrad.2010.07.025","volume":"80","author":"FW Roemer","year":"2011","unstructured":"Roemer FW, Kwoh CK, Hannon MJ, et al. Semiquantitative assessment of focal cartilage damage at 3T MRI: a comparative study of dual echo at steady state (DESS) and intermediate-weighted (IW) fat suppressed fast spin echo sequences. Eur J Radiol. 2011;80(2):e126\u201331. https:\/\/doi.org\/10.1016\/j.ejrad.2010.07.025.","journal-title":"Eur J Radiol"},{"key":"3253_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jprot.2018.04.030","volume":"190","author":"CS Thudium","year":"2019","unstructured":"Thudium CS, Lofvall H, Karsdal MA, et al. Protein biomarkers associated with pain mechanisms in osteoarthritis. J Proteomics. 2019;190:55\u201366. https:\/\/doi.org\/10.1016\/j.jprot.2018.04.030.","journal-title":"J Proteomics"},{"key":"3253_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13075-015-0913-x","volume":"18","author":"AC Bay-Jensen","year":"2016","unstructured":"Bay-Jensen AC, Platt A, Siebuhr AS, et al. Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study. Arthritis Res Ther. 2016;18:13. https:\/\/doi.org\/10.1186\/s13075-015-0913-x.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"3253_CR21","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/acr.23121","volume":"69","author":"LA Deveza","year":"2017","unstructured":"Deveza LA, Kraus VB, Collins JE, et al. Association between biochemical markers of bone turnover and bone changes on imaging: data from the Osteoarthritis Initiative. Arthritis Care Res (Hoboken). 2017;69(8):1179\u201391. https:\/\/doi.org\/10.1002\/acr.23121.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"3253_CR22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.joca.2008.07.008","volume":"17","author":"W Wirth","year":"2009","unstructured":"Wirth W, Hellio Le Graverand MP, Wyman BT, et al. Regional analysis of femorotibial cartilage loss in a subsample from the Osteoarthritis Initiative progression subcohort. Osteoarthritis Cartilage. 2009;17(3):291\u20137. https:\/\/doi.org\/10.1016\/j.joca.2008.07.008.","journal-title":"Osteoarthritis Cartilage"},{"issue":"8","key":"3253_CR23","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.joca.2011.05.004","volume":"19","author":"DJ Hunter","year":"2011","unstructured":"Hunter DJ, Guermazi A, Lo GH, et al. Evolution of semi-quantitative whole joint assessment of knee OA: MOAKS (MRI Osteoarthritis Knee Score). Osteoarthritis Cartilage. 2011;19(8):990\u20131002. https:\/\/doi.org\/10.1016\/j.joca.2011.05.004.","journal-title":"Osteoarthritis Cartilage"},{"key":"3253_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1471-2474-11-125","volume":"11","author":"MA Karsdal","year":"2010","unstructured":"Karsdal MA, Byrjalsen I, Bay-Jensen AC, et al. Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis\u2013the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation. BMC Musculoskelet Disord. 2010;11:125. https:\/\/doi.org\/10.1186\/1471-2474-11-125.","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"3253_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/annrheumdis-2016-209253","volume":"76","author":"VB Kraus","year":"2017","unstructured":"Kraus VB, Hargrove DE, Hunter DJ, et al. Establishment of reference intervals for osteoarthritis-related soluble biomarkers: the FNIH\/OARSI OA Biomarkers Consortium. Ann Rheum Dis. 2017;76(1):179\u201385. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209253.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3253_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.joca.2014.09.003","volume":"23","author":"WE Van Spil","year":"2015","unstructured":"Van Spil WE, Nair SC, Kinds MB, et al. Systemic biochemical markers of joint metabolism and inflammation in relation to radiographic parameters and pain of the knee: data from CHECK, a cohort of early-osteoarthritis subjects. Osteoarthritis Cartilage. 2015;23(1):48\u201356. https:\/\/doi.org\/10.1016\/j.joca.2014.09.003.","journal-title":"Osteoarthritis Cartilage"},{"issue":"9","key":"3253_CR27","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.joca.2021.06.008","volume":"29","author":"T Fan","year":"2021","unstructured":"Fan T, Ruan G, Antony B, et al. The interactions between MRI-detected osteophytes and bone marrow lesions or effusion-synovitis on knee symptom progression: an exploratory study. Osteoarthritis Cartilage. 2021;29(9):1296\u2013305. https:\/\/doi.org\/10.1016\/j.joca.2021.06.008.","journal-title":"Osteoarthritis Cartilage"},{"issue":"11","key":"3253_CR28","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/acr.22871","volume":"68","author":"Z Zhu","year":"2016","unstructured":"Zhu Z, Ding C, Jin X, et al. Patellofemoral bone marrow lesions: natural history and associations with pain and structure. Arthritis Care Res (Hoboken). 2016;68(11):1647\u201354. https:\/\/doi.org\/10.1002\/acr.22871.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"3253_CR29","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.3390\/jcm9103107","volume":"9","author":"N Arnold","year":"2020","unstructured":"Arnold N, Rehm M, Buchele G, et al. Growth differentiation factor-15 as a potent predictor of long-term mortality among subjects with osteoarthritis. J Clin Med. 2020;9(10):3107. https:\/\/doi.org\/10.3390\/jcm9103107.","journal-title":"J Clin Med"},{"issue":"6","key":"3253_CR30","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.semarthrit.2020.03.002","volume":"50","author":"AR Bihlet","year":"2020","unstructured":"Bihlet AR, Bjerre-Bastos JJ, Andersen JR, et al. Clinical and biochemical factors associated with risk of total joint replacement and radiographic progression in osteoarthritis: data from two phase III clinical trials. Semin Arthritis Rheum. 2020;50(6):1374\u201381. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.03.002.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"3253_CR31","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1002\/art.21366","volume":"52","author":"P Garnero","year":"2005","unstructured":"Garnero P, Peterfy C, Zaim S, et al. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum. 2005;52(9):2822\u20139.","journal-title":"Arthritis Rheum"},{"key":"3253_CR32","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3389\/fnins.2019.01016","volume":"13","author":"N Sofat","year":"2019","unstructured":"Sofat N, Ejindu V, Heron C, et al. biomarkers in painful symptomatic knee OA demonstrate that MRI assessed joint damage and type II collagen degradation products are linked to disease progression. Front Neurosci. 2019;13:1016. https:\/\/doi.org\/10.3389\/fnins.2019.01016.","journal-title":"Front Neurosci"},{"issue":"10","key":"3253_CR33","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1136\/annrheumdis-2017-211396","volume":"76","author":"A Kuttapitiya","year":"2017","unstructured":"Kuttapitiya A, Assi L, Laing K, et al. Microarray analysis of bone marrow lesions in osteoarthritis demonstrates upregulation of genes implicated in osteochondral turnover, neurogenesis and inflammation. Ann Rheum Dis. 2017;76(10):1764\u201373. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211396.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3253_CR34","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.joca.2014.06.008","volume":"22","author":"B Wang","year":"2014","unstructured":"Wang B, Pramono HK, Cicuttini FM, et al. Association between urinary C-telopeptide fragments of type II collagen and knee structure in middle-aged women without clinical knee disease. Osteoarthritis Cartilage. 2014;22(8):1136\u201341. https:\/\/doi.org\/10.1016\/j.joca.2014.06.008.","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"3253_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10195-021-00572-0","volume":"22","author":"Y Luo","year":"2021","unstructured":"Luo Y, Samuels J, Krasnokutsky S, et al. A low cartilage formation and repair endotype predicts radiographic progression of symptomatic knee osteoarthritis. J Orthop Traumatol. 2021;22(1):10. https:\/\/doi.org\/10.1186\/s10195-021-00572-0.","journal-title":"J Orthop Traumatol"},{"issue":"11","key":"3253_CR36","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.3390\/ijms19113485","volume":"19","author":"Y Luo","year":"2018","unstructured":"Luo Y, He Y, Reker D, et al. A novel high sensitivity type II collagen blood-based biomarker, PRO-C2, for assessment of cartilage formation. Int J Mol Sci. 2018;19(11):3485. https:\/\/doi.org\/10.3390\/ijms19113485.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3253_CR37","doi-asserted-by":"publisher","first-page":"18789","DOI":"10.3390\/ijms151018789","volume":"15","author":"NS Gudmann","year":"2014","unstructured":"Gudmann NS, Wang J, Hoielt S, et al. Cartilage turnover reflected by metabolic processing of type II collagen: a novel marker of anabolic function in chondrocytes. Int J Mol Sci. 2014;15(10):18789\u2013803. https:\/\/doi.org\/10.3390\/ijms151018789.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3253_CR38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.joca.2021.10.008","volume":"30","author":"AC Bay-Jensen","year":"2022","unstructured":"Bay-Jensen AC, Manginelli AA, Karsdal M, et al. Low levels of type II collagen formation (PRO-C2) are associated with response to sprifermin: a pre-defined, exploratory biomarker analysis from the FORWARD study. Osteoarthritis Cartilage. 2022;30(1):92\u20139. https:\/\/doi.org\/10.1016\/j.joca.2021.10.008.","journal-title":"Osteoarthritis Cartilage"},{"key":"3253_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/1471-2474-12-217","volume":"12","author":"JB Driban","year":"2011","unstructured":"Driban JB, Lo GH, Lee JY, et al. Quantitative bone marrow lesion size in osteoarthritic knees correlates with cartilage damage and predicts longitudinal cartilage loss. BMC Musculoskelet Disord. 2011;12:217. https:\/\/doi.org\/10.1186\/1471-2474-12-217.","journal-title":"BMC Musculoskelet Disord"},{"issue":"5","key":"3253_CR40","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3899\/jrheum.140094","volume":"41","author":"DT Felson","year":"2014","unstructured":"Felson DT. The current and future status of biomarkers in osteoarthritis. J Rheumatol. 2014;41(5):834\u20136. https:\/\/doi.org\/10.3899\/jrheum.140094.","journal-title":"J Rheumatol"},{"issue":"11","key":"3253_CR41","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1136\/annrheumdis-2013-203726","volume":"72","author":"M Lotz","year":"2013","unstructured":"Lotz M, Martel-Pelletier J, Christiansen C, et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis. 2013;72(11):1756\u201363. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203726.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3253_CR42","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.joca.2018.04.019","volume":"26","author":"GB Joseph","year":"2018","unstructured":"Joseph GB, Nevitt MC, McCulloch CE, et al. Associations between molecular biomarkers and MR-based cartilage composition and knee joint morphology: data from the Osteoarthritis Initiative. Osteoarthritis Cartilage. 2018;26(8):1070\u20137. https:\/\/doi.org\/10.1016\/j.joca.2018.04.019.","journal-title":"Osteoarthritis Cartilage"},{"issue":"7","key":"3253_CR43","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3109\/1354750x.2011.620628","volume":"16","author":"D Leeming","year":"2011","unstructured":"Leeming D, He Y, Veidal S, et al. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers. 2011;16(7):616\u201328. https:\/\/doi.org\/10.3109\/1354750x.2011.620628.","journal-title":"Biomarkers"},{"issue":"9","key":"3253_CR44","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/art.40527","volume":"70","author":"CF Kjelgaard-Petersen","year":"2018","unstructured":"Kjelgaard-Petersen CF, Platt A, Braddock M, et al. Translational biomarkers and ex vivo models of joint tissues as a tool for drug development in rheumatoid arthritis. Arthritis Rheumatol. 2018;70(9):1419\u201328. https:\/\/doi.org\/10.1002\/art.40527.","journal-title":"Arthritis Rheumatol"},{"key":"3253_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41927-019-0052-0","volume":"3","author":"AC Bay-Jensen","year":"2019","unstructured":"Bay-Jensen AC, Platt A, Jenkins MA, et al. Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. BMC Rheumatol. 2019;3:3. https:\/\/doi.org\/10.1186\/s41927-019-0052-0.","journal-title":"BMC Rheumatol"},{"issue":"7","key":"3253_CR46","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1097\/j.pain.0000000000000908","volume":"158","author":"MR Radojcic","year":"2017","unstructured":"Radojcic MR, Thudium CS, Henriksen K, et al. Biomarker of extracellular matrix remodelling C1M and proinflammatory cytokine interleukin 6 are related to synovitis and pain in end-stage knee osteoarthritis patients. Pain. 2017;158(7):1254\u201363. https:\/\/doi.org\/10.1097\/j.pain.0000000000000908.","journal-title":"Pain"},{"issue":"12","key":"3253_CR47","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1016\/j.joca.2017.09.007","volume":"25","author":"SX Wang","year":"2017","unstructured":"Wang SX, Abramson SB, Attur M, et al. Safety, tolerability, and pharmacodynamics of an anti-interleukin-1alpha\/beta dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study. Osteoarthritis Cartilage. 2017;25(12):1952\u201361. https:\/\/doi.org\/10.1016\/j.joca.2017.09.007.","journal-title":"Osteoarthritis Cartilage"},{"issue":"11","key":"3253_CR48","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.joca.2017.07.015","volume":"25","author":"RF Loeser","year":"2017","unstructured":"Loeser RF, Beavers DP, Bay-Jensen AC, et al. Effects of dietary weight loss with and without exercise on interstitial matrix turnover and tissue inflammation biomarkers in adults with knee osteoarthritis: the Intensive Diet and Exercise for Arthritis trial (IDEA). Osteoarthritis Cartilage. 2017;25(11):1822\u20138. https:\/\/doi.org\/10.1016\/j.joca.2017.07.015.","journal-title":"Osteoarthritis Cartilage"},{"issue":"3","key":"3253_CR49","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1093\/rheumatology\/keac442","volume":"62","author":"LA van de Stadt","year":"2023","unstructured":"van de Stadt LA, Kroon FPB, Thudium CF, et al. Serum biomarkers in prednisolone-treated hand osteoarthritis patients. Rheumatology (Oxford). 2023;62(3):1350\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/keac442.","journal-title":"Rheumatology (Oxford)"},{"key":"3253_CR50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13075-016-0976-3","volume":"18","author":"F Saberi Hosnijeh","year":"2016","unstructured":"Saberi Hosnijeh F, Siebuhr AS, Uitterlinden AG, et al. Association between biomarkers of tissue inflammation and progression of osteoarthritis: evidence from the Rotterdam study cohort. Arthritis Res Ther. 2016;18:81. https:\/\/doi.org\/10.1186\/s13075-016-0976-3.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"3253_CR51","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.semarthrit.2013.07.008","volume":"43","author":"AC Bay-Jensen","year":"2014","unstructured":"Bay-Jensen AC, Platt A, Byrjalsen I, et al. Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. Semin Arthritis Rheum. 2014;43(4):470\u20138. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.07.008.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"3253_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.joca.2013.10.020","volume":"22","author":"AS Siebuhr","year":"2014","unstructured":"Siebuhr AS, Petersen KK, Arendt-Nielsen L, et al. Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover. Osteoarthritis Cartilage. 2014;22(1):44\u201350. https:\/\/doi.org\/10.1016\/j.joca.2013.10.020.","journal-title":"Osteoarthritis Cartilage"},{"issue":"Suppl 2","key":"3253_CR53","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1136\/annrheumdis-2015-eular.6095","volume":"74","author":"AC Bay-Jensen","year":"2015","unstructured":"Bay-Jensen AC, Byrjalsen I, Musa K, et al. AB0839 identification of a inflammatory phenotype with higher likelihood of progression in OA: analysis of Womac Pain Sub-Questions, C3M and U-CTX-II from two phase 3 randomized clinical trials with treatment of symptomatic knee osteoarthritis. Ann Rheum Dis. 2015;74(Suppl 2):1180\u20131. https:\/\/doi.org\/10.1136\/annrheumdis-2015-eular.6095.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3253_CR54","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13075-021-02610-y","volume":"23","author":"LC Alexander Jr","year":"2021","unstructured":"Alexander LC Jr, McHorse G, Huebner JL, et al. A matrix metalloproteinase-generated neoepitope of CRP can identify knee and multi-joint inflammation in osteoarthritis. Arthritis Res Ther. 2021;23(1):226. https:\/\/doi.org\/10.1186\/s13075-021-02610-y.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"3253_CR55","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1002\/art.38856","volume":"66","author":"L Arendt-Nielsen","year":"2014","unstructured":"Arendt-Nielsen L, Eskehave TN, Egsgaard LL, et al. Association between experimental pain biomarkers and serologic markers in patients with different degrees of painful knee osteoarthritis. Arthritis Rheumatol. 2014;66(12):3317\u201326. https:\/\/doi.org\/10.1002\/art.38856.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"3253_CR56","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.3390\/ijms21113791","volume":"21","author":"S Dudli","year":"2020","unstructured":"Dudli S, Ballatori A, Bay-Jensen AC, et al. Serum biomarkers for connective tissue and basement membrane remodeling are associated with vertebral endplate bone marrow lesions as seen on MRI (Modic changes). Int J Mol Sci. 2020;21(11):3791. https:\/\/doi.org\/10.3390\/ijms21113791.","journal-title":"Int J Mol Sci"},{"key":"3253_CR57","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1016\/j.joca.2018.02.387","volume":"26","author":"AC Bay-Jensen","year":"2018","unstructured":"Bay-Jensen AC, Karsdal MA, Ladel C, et al. C1M, C2M, C3M, PRO-C2, and CRPM in serum reflect different potential pathogenetic domains of osteoarthritis, data from check. Osteoarthritis Cartilage. 2018;26:S179\u201380. https:\/\/doi.org\/10.1016\/j.joca.2018.02.387.","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"3253_CR58","doi-asserted-by":"publisher","first-page":"6583","DOI":"10.1038\/s41598-021-86064-x","volume":"11","author":"AC Bay-Jensen","year":"2021","unstructured":"Bay-Jensen AC, Bihlet A, Byrjalsen I, et al. Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis. Sci Rep. 2021;11(1):6583. https:\/\/doi.org\/10.1038\/s41598-021-86064-x.","journal-title":"Sci Rep"},{"issue":"3","key":"3253_CR59","doi-asserted-by":"publisher","first-page":"e9739","DOI":"10.1371\/journal.pone.0009739","volume":"5","author":"VB Kraus","year":"2010","unstructured":"Kraus VB, Kepler TB, Stabler T, et al. First qualification study of serum biomarkers as indicators of total body burden of osteoarthritis. PLoS ONE. 2010;5(3):e9739. https:\/\/doi.org\/10.1371\/journal.pone.0009739.","journal-title":"PLoS ONE"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03253-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03253-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03253-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T09:04:29Z","timestamp":1705568669000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03253-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3253"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03253-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"20 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The OAI study received ethical approval from each OAI clinical site and for the OAI coordinating center. All participants provided informed consent to the OAI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DJH provides consulting advice to Merck Serono, Pfizer, Lilly, TLCBio, Novartis.VBK provides consulting advice to 23andME, Bioiberica, Genascence, Novartis, Paradigm Biopharma.AG provides consulting to Pfizer, Novartis, TrialSpark, ICM, Coval, Medipost and AstraZeneca. He is Shareholder of BICL, LLC.FR is consultant to Gr\u00fcnenthal, GmbH and shareholder of Boston Imaging Core Lab (BICL), LLC.JEC provides consulting to BICL, LLC.CL provides consulting advice to Charit\u00e9, TrialSpark, Regenosine and ReumaNederland.MK and AB are full-time employee and shareholders of Nordic Bioscience.Other authors declare that they did not have any competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}